766 results on '"Rieckmann, Peter"'
Search Results
2. Going beyond PA: Assessing sensorimotor capacity with wearables in multiple sclerosis—a cross-sectional study
3. Outside the Laboratory Assessment of Upper Limb Laterality in Patients With Stroke: A Cross-Sectional Study
4. Outside the Laboratory Assessment of Upper Limb Laterality in Patients With Stroke: A Cross-Sectional Study
5. Expert opinion on the pharmacological management of multiple sclerosis in women of childbearing age in Iraq
6. Changes in thumb tapping rates and central motor conduction times are associated in persons with multiple sclerosis
7. Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT
8. Autorenverzeichnis
9. Liquor- und Blutanalyse
10. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
11. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
12. Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
13. State and trait of finger tapping performance in multiple sclerosis
14. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis
15. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis
16. Multiple Sklerose
17. The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset
18. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group
19. Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care
20. Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart®
21. Costs and Quality of Life in Multiple Sclerosis: An Observational Study in Germany
22. Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier
23. Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study
24. Can Growth Hormone Lead to a Faster Recovery from Guillain-Barré Syndrome? Case Report of the First Therapeutic Use in One Patient
25. Autorenverzeichnis
26. Erweiterte Liquor- und Blutanalyse
27. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary
28. Functional clinical outcomes in multiple sclerosis: Current status and future prospects
29. Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group
30. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
31. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary
32. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
33. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
34. Growth hormone leading to faster recovery in pure motor Guillain-Barre syndrome: report of the first off-label use in one patient
35. PO136 Durable efficacy of cladribine tablets: clarity+extension
36. PO138 High disease activity in relapsing multiple sclerosis (rms)
37. PO137 Efficacy of cladribine tablets in high disease activity rms
38. Cladribine tablets for relapsing–remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study
39. 016 Long-term disease stability in patients treated with cladribine tablets in CLARITY and CLARITY extension
40. Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial
41. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
42. The Association Between Actigraphy-Derived Behavioral Clusters and Self-Reported Fatigue in Persons With Multiple Sclerosis: Cross-sectional Study
43. Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
44. Assessment of microRNA-related SNP effects in the 3′ untranslated region of the IL22RA2 risk locus in multiple sclerosis
45. Herausgeber- und Autorenadressen
46. Neurobiologische Effekte körperlicher Aktivität
47. Marker des Liquor cerebrospinalis und des Blutes im Überblick
48. Autorenverzeichnis
49. Herausgeber- und Autorenadressen
50. Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.